Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC Retiree Rx Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Blue Retiree Rx 2026 Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 formulary (Drug List) for Blue Retiree Rx and describes which prescription drugs are covered, who to contact, and the plan rules (prior authorization, quantity limits, step therapy, tiering and cost-sharing) that apply to members of the Blue Retiree Rx plan.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlue Retiree Rx 2026 Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MonthlyFormulary updates
    $615Deductible (Tiers 2-5)
    72 / 24Decision time for exceptions
    26220Formulary ID
    ~200+Distinct listed drugs (excerpt)

    Coverage Criteria

    General Coverage Conditions

    Covered drugs when plan rules are followed

    Plan coverage conditions: Drug is listed on the formulary OR an approved exception exists; drug is medically necessary for the member; prescription is filled at a Blue Retiree Rx network pharmacy; other plan rules (e.g., Prior Authorization, Step Therapy, Quantity Limits) applicable to the product are satisfied.

    Summary reflects general formulary coverage statements and conditions for coverage from the formulary introduction.

    Formulary Exception Criteria

    Exception will be approved when prescriber documents medical necessity relative to formulary alternatives

    Exception approval: Prescriber provides a supporting statement explaining why the alternative formulary drugs, lower cost-sharing drugs, or applying the restriction would not be as effective or would cause adverse effects; the plan reviews the request and issues a decision within 72 hours of receiving the prescriber's supporting statement (24 hours if expedited).72 hours / 24 hours expedited
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlue Retiree Rx 2026 Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' before dispensing to ensure coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Formulary MetadataProvider Actions and Operational RequirementsStep Therapy RulesQuantity Limits (QL) by ProductSite of Care and DispensingDefinitions and Key TermsBackground

    Operational timelines and required prescriber statement per formulary exception process.

    Formulary coverage and cost-sharing

    Covered when drug is on formulary and meets any listed Requirements/Limits for that product

    Tier placement and cost-sharing: Drug is assigned to a formulary tier and member cost-sharing (retail, mail order, or long-term care) applies as listed; deductible of $615 applies to Tiers 2–5 where indicated.$615 deductible on Tiers 2-5

    Examples in the formulary show tier-specific copays/coinsurance and site-of-care variations (retail, mail order, LTC).

    Requirements/Limits conformance: Drug claims must meet any Requirements/Limits shown for the product (e.g., PA, QL, ST, B/D) to be covered under the formulary terms.varies by product (see QL values in table)

    Quantity limits and prior authorization obligations are applied per product entries in the Requirements/Limits table.

    Formulary tier and utilization management annotations

    Formulary coverage is indicated by drug-tier assignment plus Requirements/Limits flags; specific medical necessity criteria are referenced elsewhere in the formulary or PA process.

    Formulary entry annotation: Each formulary line lists a Drug Tier and a Requirements/Limits annotation (examples include 'PA', 'PA NSO', and 'QL(...)').

    These annotations define utilization management requirements; clinical medical-necessity criteria for PA are found in the plan's authorization procedures.

    Common annotations: Examples of annotations: 'PA NSO' (prior authorization non-standard ordering), 'PA' (prior authorization), 'QL(## EA per ## days)' (quantity limit), 'ST' or 'ST NSO' (step therapy), 'B/D' (benefit/dispensing designation).

    See Requirements/Limits Key entries for product-specific annotations and quantities.

    Coverage requirements (PA, QL, ST)

    Drugs listed are covered per formulary but may have the following requirements:

    PA_required: Items marked 'PA' require prior authorization before coverage.

    Examples in the formulary include many specialty products (e.g., SPEVIGO, LIVMARLI) that are listed with PA.

    Quantity_limit: Items with 'QL(...)' are subject to quantity limits for a specified time period; claims exceeding the limit require prior approval or exception.QL values vary by product (see table entries)

    Examples: topical products (grams per 30 days) and specialty injectables (mL per 28/30 days).

    Step_or_Sequence: Items annotated 'ST' or 'ST NSO' require Step Therapy per plan rules (trial of preferred agents prior to coverage of non-preferred agents).

    Specific step sequences and required prior therapies are defined in the formulary introduction or PA criteria.

    Formulary product-specific coverage rules

    Coverage entries list product, drug tier, and Requirements/Limits such as QL, PA, or B/D designations.

    Product line entries: Each product row includes: product name, strength/formulation, Drug Tier, and Requirements/Limits (examples: QL(30 EA per 30 days); PA; B/D; QL(200 EA per 30 days) for pen needles).varies by product

    Extract specific product rules directly from the Requirements/Limits table for operational use.

    If a drug is withdrawn from sale by the manufacturer or the FDA determines it is withdrawn for safety or effectiveness reasons, the plan may immediately remove the drug from the formulary and it will not be covered. The formulary text states the plan may later provide notice to affected members and that members or prescribers may request an exception to continue coverage under the plan's exception process.

    Certain Tier 5 (Specialty) listings and some Covered Insulin rows in the formulary are specifically shown as Not Covered for particular subitems or positions in the tier table. Providers should consult the formulary rows for the insulin or specialty product to determine whether the specific presentation or subitem is marked Not Covered.

    Within the excerpt no additional explicit coverage exclusions are listed in-line; instead the table directs readers to the formulary introduction for definitions of symbols and abbreviations used in the Requirements/Limits column. Refer to the introduction pages for the precise meaning of table symbols and any exclusion notation.

    This excerpt does not enumerate clinical indication–based exclusions for products. The table notes that symbol and abbreviation meanings (for example, PA, QL, ST, PA NSO) are defined on the formulary introduction pages; consult those introduction pages for any indication‑specific coverage rules or exclusions.

    No explicit statements labeling any drug or use as 'Not Medically Necessary' appear in the provided excerpt. The Requirements/Limits key references PA/PA NSO and other flags, with definitions and the broader medical‑necessity rules described on the formulary introduction pages.

    Coding and Formulary Metadata

    Requirements / Limits codes and examplesmixed
    QL(30 EA per 90 days)Quantity limit for JOURNAVX TABLET 50MG
    QL(60 EA per 30 days)Quantity limit for celecoxib formulations
    QL(1000 GM per 30 days)Quantity limit for diclofenac sodium gel 1%
    QL(4 EA per 28 days)Quantity limit for buprenorphine patch weekly
    NDSNon-Extended Day Supply (various listed drugs)
    PAPrior Authorization (applies to certain products e.g., fentanyl lozenges)
    Opioid analgesics and combinations (partial)mixed
    hydromorphone hcl tablet 8mglisted drug and strength; Drug Tier = 4; Requirements/Limits = NDS.
    hydromorphone hydrochloride injection 1mg/ml, 2mg/ml, 50mg/5mllisted drug and strengths; Drug Tier = 4; Requirements/Limits = NDS.
    morphine sulfate injection 10mg/ml, 4mg/mlDrug Tier = 4; Requirements/Limits = NDS.
    morphine sulfate oral solution 100mg/5ml, 10mg/5ml, 20mg/5mlDrug Tier = 3; Requirements/Limits = NDS.
    morphine sulfate tablet 15mg, 30mgDrug Tier = 3; Requirements/Limits = NDS.
    oxycodone hydrochloride solution 5mg/5mlDrug Tier = 4; Requirements/Limits = NDS.
    oxycodone hydrochloride tablet 10mg, 15mg, 5mgDrug Tier = 2; Requirements/Limits = NDS.
    oxycodone hydrochloride tablet 20mg, 30mgDrug Tier = 3; Requirements/Limits = NDS.
    oxycodone/acetaminophen tablet 325mg; 5mgDrug Tier = 2; Requirements/Limits = NDS.
    oxycodone/acetaminophen tablet 325mg; 10mg, 325mg; 7.5mgDrug Tier = 3; Requirements/Limits = NDS.
    Analgesics and local anesthetics (partial)mixed
    oxycodone/acetaminophen tablet 325mg; 2.5mgDrug Tier = 4; Requirements/Limits = NDS.
    tramadol hydrochloride/acetaminophen tablet 325mg; 37.5mgDrug Tier = 2; Requirements/Limits = NDS.
    tramadol hydrochloride tablet 50mgDrug Tier = 2; Requirements/Limits = NDS.
    lidocaine/prilocaine cream 2.5%; 2.5%Drug Tier = 3; Requirements/Limits = QL(30 GM per 30 days); PA.
    lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    lidocaine patch 5%Drug Tier = 4; Requirements/Limits = PA.
    premium lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    Substance use and opioid reversal agents (partial)mixed
    acamprosate calcium dr tablet delayed release 333mgDrug Tier = 4; Requirements/Limits = .
    disulfiram tablet 250mg, 500mgDrug Tier = 3; Requirements/Limits = .
    naltrexone hydrochloride tablet 50mgDrug Tier = 2; Requirements/Limits = .
    VIVITROL INJECTION 380MGDrug Tier = 5; Requirements/Limits = .
    buprenorphine hcl/naloxone hcl tablet sublingual 2mg; 0.5mgDrug Tier = 2; Requirements/Limits = .
    buprenorphine hcl tablet sublingual 2mg, 8mgDrug Tier = 2; Requirements/Limits = .
    KLOXXADO LIQUID 8MG/0.1MLDrug Tier = 4; Requirements/Limits = .
    naloxone hcl injection 4mg/10mlDrug Tier = 2; Requirements/Limits = .
    naloxone hydrochloride injection 0.4mg/mlDrug Tier = 2; Requirements/Limits = .
    Antibacterials and related classes (grouped summary)mixed
    multiple antibacterials, cephalosporins, penicillins, carbapenems, macrolides, quinolones, tetracyclines, sulfonamides, aminoglycosidesMany individual products listed with tiers and occasional QL/PA flags (see chunks for specifics).
    Formulary drug entries and tier/requirement annotationsmixed
    OJEMDA TABLET 100MGListed with Drug Tier = 5; Requirements/Limits = PA NSO
    ONUREG TABLET 200MG, 300MGListed with Drug Tier = 5; Requirements/Limits = PA NSO
    PHESGO INJECTION 2000UNIT/ML; 60MG/ML; 80MG/ML; 40MG/MLDrug Tier = 5; Requirements/Limits = PA NSO
    REVUFORJ TABLET 110MG, 160MG, 25MGDrug Tier = 5; Requirements/Limits = PA NSO
    VONJO CAPSULE 100MGDrug Tier = 5; Requirements/Limits = PA NSO
    ZOLINZA CAPSULE 100MGDrug Tier = 5; Requirements/Limits = PA NSO
    anastrozole tablet 1mgDrug Tier = 2
    exemestane tablet 25mgDrug Tier = 4
    letrozole tablet 2.5mgDrug Tier = 2
    ALECENSA CAPSULE 150MGDrug Tier = 5; Requirements/Limits = PA NSO
    1–10 of 19
    1/2
    Antiprotozoals and related agents (partial)NDC/mfg description
    praziquantel 600mgpraziquantel tablet 600mg
    ALINIA 100MG/5MLALINIA SUSPENSION RECONSTITUTED 100MG/5ML
    atovaquone/proguanil 62.5mg/25mgatovaquone/proguanil hcl tablet 62.5mg; 25mg
    atovaquone/proguanil 250mg/100mgatovaquone/proguanil hydrochloride tablet 250mg; 100mg
    atovaquone suspension 750mg/5mlatovaquone suspension 750mg/5ml
    benznidazole 100mgbenznidazole tablet 100mg, 12.5mg
    chloroquine phosphate 250mg/500mgchloroquine phosphate tablet 250mg, 500mg
    COARTEM 20mg/120mgCOARTEM TABLET 20MG; 120MG
    hydroxychloroquine 100mg/200mghydroxychloroquine sulfate tablet 100mg, 200mg
    mefloquine 250mgmefloquine hydrochloride tablet 250mg
    Additional antiparasitic agents (partial)NDC/mfg description
    nitazoxanide 500mgnitazoxanide tablet 500mg
    pentamidine injection 300mgpentamidine isethionate injection 300mg
    primaquine 26.3mgprimaquine phosphate tablet 26.3mg
    pyrimethamine 25mgpyrimethamine tablet 25mg
    quinine sulfate 324mgquinine sulfate capsule 324mg
    Assorted CNS, antiviral, and HIV therapy products (partial)NDC/mfg description
    benztropine 0.5/1/2mgbenztropine mesylate tablet 0.5mg, 1mg, 2mg
    trihexyphenidyl 2mg/5mgtrihexyphenidyl hydrochloride tablet 2mg, 5mg
    entacapone 200mgentacapone tablet 200mg
    pramipexole 0.125-1.5mgpramipexole dihydrochloride tablet 0.125mg - 1.5mg
    ropinirole 0.5-5mgropinirole hcl tablet 0.5mg - 5mg
    carbidopa/levodopa ERcarbidopa/levodopa er tablet extended release
    INBRIJA 42mgINBRIJA CAPSULE 42MG
    aripiprazole formulationsaripiprazole odt, solution, tablet (various strengths)
    CAPLYTACAPLYTA CAPSULE 10.5MG, 21MG, 42MG
    NUPLAZIDNUPLAZID CAPSULE 34MG; TABLET 10MG
    1–10 of 20
    1/2
    Quantity limit codes shown in excerptmixed
    QL(60 EA per 30 days)Quantity limit for dabigatran etexilate capsule
    QL(148 EA per 365 days)Quantity limit for ELIQUIS STARTER PACK TABLET THERAPY PACK
    QL(84 EA per 28 days)Quantity limit for ELIQUIS CAPSULE SPRINKLE 0.15MG
    QL(140 EA per 28 days)Quantity limit for ELIQUIS TABLET SOLUBLE 0.5MG
    QL(420 EA per 28 days)Alternate QL for ELIQUIS TABLET SOLUBLE 0.5MG
    QL(560 EA per 28 days)Alternate QL for ELIQUIS TABLET SOLUBLE 0.5MG
    QL(30 EA per 30 days)Quantity limit for XARELTO TABLET 10MG, 20MG
    QL(360 EA per 30 days)Quantity limit for XARELTO TABLET 2.5MG
    QL(600 ML per 30 days)Quantity limit for XARELTO SUSPENSION RECONSTITUTED 1MG/ML
    QL(148 EA per 365 days)ELIQUIS starter pack (duplicate listing)
    1–10 of 13
    1/2
    Selected specialty/formulary entries with limits/PA/STmixed
    SPEVIGO INJECTION 150MG/ML, 300MG/2MLListed with QL(4 ML per 28 days); PA
    OTEZLA TABLET 20MG, 30MGListed with QL(60 EA per 30 days); PA
    LIVMARLI SOLUTION 19MG/MLListed with QL(60 ML per 30 days); PA
    LIVMARLI TABLET 30MGListed with QL(30 EA per 30 days); PA
    RELlSTOR INJECTION 8MG/0.4MLListed with QL(12 ML per 30 days); ST
    Topical dermatologic agents and QLsmixed
    fluocinonide cream 0.05%QL(60 GM per 30 days)
    fluocinonide cream 0.1%QL(120 GM per 30 days) per segment (cream 0.1% listed with 120 GM elsewhere)
    clotrimazole/betamethasone dipropionate cream 0.05%;1%QL(90 GM per 30 days)
    diclofenac sodium gel 3%QL(300 GM per 30 days); ST
    Formulary metadatamixed
    Formulary ID: 26220Formulary identifier shown in multiple chunks
    Quantity limits and formulary indicatorsmixed
    QL(200 EA per 30 days)Quantity limit example for pen needles/insulin syringes and similar supplies
    QL(1 EA per 365 days)Quantity limit example for introductory kits (Omnipod, etc.)
    QL(30 EA per 30 days)Quantity limit example for Omnipod pods and similar supplies
    QL(0.8 ML per 28 days)Quantity limit for RIVFLOZA INJECTION 128MG/0.8ML
    QL(1 ML per 28 days)Quantity limit for RIVFLOZA INJECTION 160MG/ML, 80MG/0.5ML
    QL(90 EA per 30 days)Quantity limit example for SKYCLARYS CAPSULE 50MG
    QL(60 ML per 28 days)Quantity limit for CYSTARAN SOLUTION 0.44%
    QL(2.5 ML per 25 days)Quantity limit for RHOPRESSA and LUMIGAN
    QL(10 ML per 42 days)Quantity limit for XDEMVY SOLUTION 0.25%
    QL(12 ML per 365 days)Quantity limit for bromfenac sodium solution 0.07%
    1–10 of 18
    1/2
    Opioid analgesics and combinations (partial)mixed
    hydromorphone hcl tablet 8mglisted drug and strength; Drug Tier = 4; Requirements/Limits = NDS.
    hydromorphone hcl injection 10mg/ml, 4mg/mlDrug Tier = 4; Requirements/Limits = NDS.
    hydromorphone hydrochloride injection 1mg/ml, 2mg/ml, 50mg/5mllisted drug and strengths; Drug Tier = 4; Requirements/Limits = NDS.
    fentanyl citrate oral transmucosal lozenge on a handle 200mcgDrug Tier = 4; Requirements/Limits = PA; NDS.
    fentanyl citrate oral transmucosal lozenge on a handle 1200mcg, 1600mcg, 400mcg, 600mcg, 800mcgDrug Tier = 5; Requirements/Limits = PA; NDS.
    methadone hcl solution 5mg/5mlDrug Tier = 3; Requirements/Limits = NDS.
    methadone hcl tablet 10mg, 5mgDrug Tier = 2; Requirements/Limits = NDS.
    morphine sulfate er tablet extended release 15mg, 30mg, 60mgDrug Tier = 3; Requirements/Limits = NDS.
    XTAMPZA ER CAPSULE ER 12 HOUR ABUSE-DETERRENTVarious strengths; Requirements/Limits = NDS.
    oxycodone/acetaminophen combinationsmultiple strengths listed with NDS across tiers
    Analgesics and local anesthetics (partial)mixed
    lidocaine/prilocaine cream 2.5%;2.5%Drug Tier = 3; Requirements/Limits = QL(30 GM per 30 days); PA.
    lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    premium lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    lidocaine patch 5%Drug Tier = 4; Requirements/Limits = PA.
    tramadol hydrochloride tablet 50mgDrug Tier = 2; Requirements/Limits = NDS.
    tramadol hydrochloride/acetaminophen tablet 325mg;37.5mgDrug Tier = 2; Requirements/Limits = NDS.
    Requirements / Limits codes and examplesmixed
    NDSNon-Extended Day Supply (various listed drugs)
    PAPrior Authorization (applies to certain products e.g., fentanyl lozenges)
    QL(30 EA per 90 days)Quantity limit for JOURNAVX TABLET 50MG
    QL(60 EA per 30 days)Quantity limit for celecoxib formulations
    QL(1000 GM per 30 days)Quantity limit for diclofenac sodium gel 1%
    QL(4 EA per 28 days)Quantity limit for buprenorphine patch weekly
    Analgesics and local anesthetics (partial)mixed
    lidocaine/prilocaine cream 2.5%; 2.5%Drug Tier = 3; Requirements/Limits = QL(30 GM per 30 days); PA.
    lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    lidocaine patch 5%Drug Tier = 4; Requirements/Limits = PA.
    premium lidocaine ointment 5%Drug Tier = 3; Requirements/Limits = QL(150 GM per 30 days); PA.
    tramadol hydrochloride tablet 50mgDrug Tier = 2; Requirements/Limits = NDS.
    tramadol hydrochloride/acetaminophen tablet 325mg; 37.5mgDrug Tier = 2; Requirements/Limits = NDS.
    linezolid suspension reconstituted 100mg/5mlDrug Tier = 5; Requirements/Limits = QL(1800 ML per 28 days).
    Antibacterials and related classes (grouped summary)mixed
    linezolid tablet 600mgDrug Tier = 4; Requirements/Limits = QL(56 EA per 28 days).
    vancomycin hydrochloride capsule 125mgDrug Tier = 4; Requirements/Limits = QL(120 EA per 30 days).
    vancomycin hydrochloride capsule 250mgDrug Tier = 4; Requirements/Limits = QL(240 EA per 30 days).
    Substance use and opioid reversal agents (partial)mixed
    buprenorphine patch weekly 10mcg/hr, 15mcg/hr, 20mcg/hrRequirements/Limits = QL(4 EA per 28 days); NDS.
    fentanyl patch 72 hour (various strengths)Requirements/Limits = NDS; some strengths PA noted elsewhere.
    Substance use and opioid reversal agents (partial)mixed
    acamprosate calcium dr tablet delayed release 333mgDrug Tier = 4; Requirements/Limits = .
    disulfiram tablet 250mg, 500mgDrug Tier = 3; Requirements/Limits = .
    naltrexone hydrochloride tablet 50mgDrug Tier = 2; Requirements/Limits = .
    VIVITROL INJECTION 380MGDrug Tier = 5; Requirements/Limits = .
    buprenorphine hcl/naloxone hcl tablet sublingual 2mg; 0.5mgDrug Tier = 2; Requirements/Limits = .
    buprenorphine hcl tablet sublingual 2mg, 8mgDrug Tier = 2; Requirements/Limits = .
    KLOXXADO LIQUID 8MG/0.1MLDrug Tier = 4; Requirements/Limits = .
    naloxone hcl injection 4mg/10mlDrug Tier = 2; Requirements/Limits = .
    naloxone hydrochloride injection 0.4mg/mlDrug Tier = 2; Requirements/Limits = .
    Smoking Cessation Agents and Antibacterials (excerpt)mixed
    bupropion hydrochloride er (sr) tablet 150mgDrug Tier = 2; Requirements/Limits = QL(60 EA per 30 days).
    amikacin sulfate injection 500mg/2mlDrug Tier = 4; Requirements/Limits = .
    ARIKAYCE SUSPENSION 590MG/8.4MLDrug Tier = 5; Requirements/Limits = PA.
    Opioid Dependence and Reversalmixed
    buprenorphine hydrochloride/naloxone hydrochloride film (various strengths)Drug Tier = 3; Requirements/Limits = .
    OPVEE SOLUTION 2.7MG/0.1MLDrug Tier = 3; Requirements/Limits = .
    Antiprotozoals and related agents (partial)NDC/mfg description
    praziquantel 600mgpraziquantel tablet 600mg
    ALINIA 100MG/5MLALINIA SUSPENSION RECONSTITUTED 100MG/5ML
    atovaquone/proguanil 62.5mg/25mgatovaquone/proguanil hcl tablet 62.5mg; 25mg
    atovaquone/proguanil 250mg/100mgatovaquone/proguanil hydrochloride tablet 250mg; 100mg
    atovaquone suspension 750mg/5mlatovaquone suspension 750mg/5ml
    benznidazole 100mgbenznidazole tablet 100mg, 12.5mg
    chloroquine phosphate 250mg/500mgchloroquine phosphate tablet 250mg, 500mg
    COARTEM 20mg/120mgCOARTEM TABLET 20MG; 120MG
    hydroxychloroquine 100mg/200mghydroxychloroquine sulfate tablet 100mg, 200mg
    mefloquine 250mgmefloquine hydrochloride tablet 250mg
    Additional antiparasitic agents (partial)NDC/mfg description
    nitazoxanide 500mgnitazoxanide tablet 500mg
    pentamidine injection 300mgpentamidine isethionate injection 300mg
    primaquine 26.3mgprimaquine phosphate tablet 26.3mg
    pyrimethamine 25mgpyrimethamine tablet 25mg
    quinine sulfate 324mgquinine sulfate capsule 324mg
    Anti-hepatitis and HCV agentsmixed
    MAVYRET PACKET 50MG; 20MGMAVYRET PACKET — QL(560 EA per 365 days); PA
    MAVYRET TABLET 100MG; 40MGMAVYRET TABLET — QL(336 EA per 365 days); PA
    VOSEVI TABLET 400MG;100MG;100MGVOSEVI TABLET — QL(84 EA per 365 days); PA
    Formulary drug entries and tier/requirement annotationsmixed
    OJEMDA TABLET 100MGListed with Drug Tier = 5; Requirements/Limits = PA NSO
    ONUREG TABLET 200MG, 300MGListed with Drug Tier = 5; Requirements/Limits = PA NSO
    PHESGO INJECTION 2000UNIT/ML; 60MG/ML; 80MG/ML; 40MG/MLDrug Tier = 5; Requirements/Limits = PA NSO
    REVUFORJ TABLET 110MG, 160MG, 25MGDrug Tier = 5; Requirements/Limits = PA NSO
    VONJO CAPSULE 100MGDrug Tier = 5; Requirements/Limits = PA NSO
    ZOLINZA CAPSULE 100MGDrug Tier = 5; Requirements/Limits = PA NSO
    ALECENSA CAPSULE 150MGDrug Tier = 5; Requirements/Limits = PA NSO
    ALUNBRIG TABLET 30MG, 180MG, THERAPY PACKDrug Tier = 5; Requirements/Limits include QL (various) and PA NSO
    AYVAKIT TABLET 25MG - 300MGDrug Tier = 5; Requirements/Limits = QL(30 EA per 30 days); PA NSO
    CABOMETYX TABLET 20MG, 40MG, 60MGDrug Tier = 5; some strengths QL(30 EA per 30 days); PA NSO
    1–10 of 16
    1/2
    Antiprotozoals and related agents (partial)NDC/mfg description
    chloroquine phosphate 250mg/500mgchloroquine phosphate tablet 250mg, 500mg
    ALINIA 100MG/5MLALINIA SUSPENSION RECONSTITUTED 100MG/5ML
    atovaquone/proguanil 62.5mg/25mgatovaquone/proguanil hcl tablet 62.5mg; 25mg
    Formulary metadatamixed
    Formulary ID: 26220Formulary identifier shown in multiple chunks
    Assorted CNS, antiviral, and HIV therapy products (partial)NDC/mfg description
    benztropine 0.5/1/2mgbenztropine mesylate tablet 0.5mg, 1mg, 2mg
    trihexyphenidyl 2mg/5mgtrihexyphenidyl hydrochloride tablet 2mg, 5mg
    entacapone 200mgentacapone tablet 200mg
    pramipexole 0.125-1.5mgpramipexole dihydrochloride tablet 0.125mg - 1.5mg
    ropinirole 0.5-5mgropinirole hcl tablet 0.5mg - 5mg
    carbidopa/levodopa ERcarbidopa/levodopa er tablet extended release
    INBRIJA 42mgINBRIJA CAPSULE 42MG
    aripiprazole formulationsaripiprazole odt, solution, tablet (various strengths)
    baclofen 5/10/20mgbaclofen tablet 5mg, 10mg, 20mg
    dantrolene 25/100mgdantrolene sodium capsule 25mg, 100mg
    1–10 of 18
    1/2
    Topical dermatologic agents and QLsmixed
    fluocinonide cream 0.05%QL(60 GM per 30 days)
    fluocinonide cream 0.1%QL(120 GM per 30 days)
    clotrimazole/betamethasone dipropionate cream 0.05%;1%QL(90 GM per 30 days)
    diclofenac sodium gel 3%QL(300 GM per 30 days); ST
    Antivirals and Hepatitis agentsmixed
    LIVTENCITY 200mgLIVTENCITY TABLET 200MG
    PREVYMIS PACKETPREVYMIS PACKET 120MG, 20MG — listed
    valganciclovir 50mg/mlvalganciclovir hydrochloride solution reconstituted 50mg/ml
    entecavir 0.5/1mgentecavir tablet 0.5mg, 1mg
    MAVYRETMAVYRET PACKET/TABLET — QL and PA as listed
    Quantity limit codes shown in excerptmixed
    QL(60 EA per 30 days)Quantity limit for dabigatran etexilate capsule
    QL(148 EA per 365 days)ELIQUIS STARTER PACK TABLET THERAPY PACK
    QL(84 EA per 28 days)ELIQUIS CAPSULE SPRINKLE
    QL(30 EA per 30 days)XARELTO TABLET 10MG, 20MG
    QL(600 ML per 30 days)XARELTO SUSPENSION RECONSTITUTED 1MG/ML
    QL(3 ML per 28 days)REPATHA (both forms)
    QL(3 ML per 28 days)TRYNGOLZA injection QL
    QL(30 EA per 30 days)KERENDIA tablet QL(30 EA per 30 days)
    QL(30 EA per 30 days)FARXIGA/JARDIANCE tablet QL examples
    Selected specialty/formulary entries with limits/PA/STmixed
    SPEVIGO INJECTION 150MG/ML, 300MG/2MLQL(4 ML per 28 days); PA
    OTEZLA TABLET 20MG, 30MGQL(60 EA per 30 days); PA
    LIVMARLI SOLUTION 19MG/MLQL(60 ML per 30 days); PA
    LIVMARLI TABLET 10/15/20MGQL(60 EA per 30 days); PA
    RELlSTOR INJECTION 8MG/0.4MLListed with QL(12 ML per 30 days); ST
    Formulary product-specific coverage rulesmixed
    LIVMARLI TABLETQL(60 EA per 30 days); PA
    JYNARQUE TABLET 15MG, 30MGQL(120 EA per 30 days); PA
    FABRAZYME INJECTIONListed with PA and QL examples
    Topical dermatologic agents and QLsmixed
    EUCRISA OINTMENT 2%Requirements/Limits = QL(120 GM per 30 days)
    fluocinonide cream 0.05%Requirements/Limits = QL(60 GM per 30 days)
    fluocinonide cream 0.1%Requirements/Limits = QL(120 GM per 30 days)
    clotrimazole/betamethasone dipropionate cream 0.05%;1%Requirements/Limits = QL(90 GM per 30 days)
    diclofenac sodium gel 3%Requirements/Limits = QL(300 GM per 30 days); ST
    Quantity limits and formulary indicatorsmixed
    QL(60 GM per 30 days)Common topical QL example
    QL(90 GM per 30 days)Topical QL example
    QL(120 GM per 30 days)Topical QL example
    STStep Therapy notation (applies to some topical products)
    Formulary metadatamixed
    Formulary ID: 26220Formulary identifier shown in multiple chunks
    Quantity limits and formulary indicatorsmixed
    QL(200 EA per 30 days)Quantity limit example for pen needles/insulin syringes and similar supplies
    QL(1 EA per 365 days)Quantity limit example for introductory kits (Omnipod, etc.)
    QL(30 EA per 30 days)Quantity limit example for Omnipod pods and similar supplies
    QL(0.8 ML per 28 days)Quantity limit for RIVFLOZA INJECTION 128MG/0.8ML
    QL(1 ML per 28 days)Quantity limit for RIVFLOZA INJECTION 160MG/ML, 80MG/0.5ML
    QL(90 EA per 30 days)Quantity limit example for SKYCLARYS CAPSULE 50MG
    QL(60 ML per 28 days)Quantity limit for CYSTARAN SOLUTION 0.44%
    QL(2.5 ML per 25 days)Quantity limit for RHOPRESSA and LUMIGAN
    QL(10 ML per 42 days)Quantity limit for XDEMVY SOLUTION 0.25%
    QL(12 ML per 365 days)Quantity limit for bromfenac sodium solution 0.07%
    1–10 of 20
    1/2
    Deductible applied to Tiers 2-5$615 on Tiers 2, 3, 4 and 5
    Effective/Formulary versionFormulary ID: 26220; Version: 13; Effective Date: 05/01/2026
    Last updatedLast Updated: 04/01/2026
    Deductible for Tiers 2-5$615
    Example preferred retail copaysTier 2 preferred retail examples shown (e.g., $17 / $34) in formulary pricing rows
    Coinsurance examplesSome tiers show percentage coinsurance (e.g., 17%); specialty tiers may show 25% or 50% for insulin in some rows
    Lidocaine/prilocaine cream QLQL(30 GM per 30 days)
    Lidocaine ointment QLQL(150 GM per 30 days)
    Lidocaine patchPA (patch listed with PA); check Requirements/Limits
    Lidocaine ointment QLQL(150 GM per 30 days)
    Premium lidocaine ointmentQL(150 GM per 30 days)
    Associated requirementPA noted for some lidocaine topical entries
    Linezolid suspension QLQL(1800 ML per 28 days)
    Linezolid injection/tablet entriesLinezolid injection 600mg/300ml listed (no QL); see tablet/suspension QLs
    Tier assignmentLinezolid suspension listed Tier = 5; linezolid tablet listed Tier = 4
    Linezolid tablet QLQL(56 EA per 28 days)
    Linezolid tablet strengthlinezolid tablet 600mg listed
    Tier assignmentLinezolid tablet listed Tier = 4
    Vancomycin capsule QLsQL(120 EA per 30 days) for 125mg; QL(240 EA per 30 days) for 250mg
    Vancomycin injection entriesMultiple vancomycin injection strengths listed (no QL) in the table
    Tier assignmentVancomycin capsules listed Tier = 4
    Quantity limits examples (common per-30-day)Examples shown include QL(30 EA per 30 days), QL(60 EA per 30 days), QL(90 EA per 30 days), QL(120 EA per 30 days)
    Larger-volume examplesExamples include QL(750 ML per 30 days), QL(540 ML per 30 days), QL(360 ML per 30 days)
    Extended/annual examplesExamples include QL(336 EA per 365 days) and QL(560 EA per 365 days)
    Additional quantity-limit examplesExamples include QL(30 EA per 30 days), QL(60 EA per 30 days), QL(750 ML per 30 days), QL(540 ML per 30 days), QL(336 EA per 365 days)
    Aripiprazole examplesaripiprazole odt QL(60 EA per 30 days); solution QL(750 ML per 30 days)
    MAVYRET / VOSEVI HCV examplesMAVYRET QL(560 EA per 365 days packet) or QL(336 EA per 365 days tablet); VOSEVI QL(84 EA per 365 days)
    Example QL (CABLIVI)QL(120 EA per 30 days) shown for CABLIVI injection example in the table
    CABLIVI listing contextCABLIVI INJECTION 11MG listed with QL in product-specific entries
    Refer to table for strength-specific QLsExact QL varies by product strength as shown in rows
    Common topical QLsCommon topical limits include QL(60 GM per 30 days); QL(90 GM per 30 days); QL(120 GM per 30 days)
    Fluocinonide cream examplefluocinonide cream 0.05% = QL(60 GM per 30 days); fluocinonide cream 0.1% also listed in topical group
    Diclofenac geldiclofenac sodium gel 3% = QL(300 GM per 30 days) and marked ST
    Specialty injectable QLs (examples)Examples include SPEVIGO QL(4 ML per 28 days) and RELISTOR injection QL(12 ML per 30 days)
    LIVMARLI exampleLIVMARLI solution 19mg/mL = QL(60 ML per 30 days); LIVMARLI tablet also shown with QL
    OTEZLA exampleOTEZLA tablet = QL(60 EA per 30 days) and PA
    Quantity limits additional examplesMultiple explicit values appear across product rows (e.g., QL(200 EA per 30 days); QL(240 ML per 30 days); QL(30 EA per 30 days); QL(91 EA per 91 days))
    Omnipod/kit examplesOMNIPOD intro kits QL(1 EA per 365 days); OMNIPOD pods QL(30 EA per 30 days)
    Pen needles/syringesBD pen needles/insulin syringes = QL(200 EA per 30 days)

    Provider Actions and Operational Requirements

    Prior Authorization

    Obtain prior authorization for PA‑listed drugs

    Prescribers must obtain prior authorization (PA) from Blue Retiree Rx before dispensing drugs that are marked 'PA' in the Requirements/Limits column; claims for these products may be denied if PA is not approved.

    • PA is defined in the Requirements/Limits Key as Prior Authorization.
    • Failure to obtain PA may result in the plan not covering the drug.
    Prior Authorization

    Request PA for select products (e.g., fentanyl lozenges)

    Some specific products in the formulary require prior authorization as shown in the Requirements/Limits listing (examples include fentanyl citrate oral transmucosal lozenges marked PA; NDS may also apply).

    • Fentanyl citrate oral transmucosal lozenge on a handle entries show 'PA; NDS'.
    • Check the Requirements/Limits field on the product row for PA indication.
    Prior Authorization

    PA required and adhere to quantity limits

    Prior authorization is required for products designated 'PA' and many entries also include quantity limits (QL); providers must secure PA and ensure dispensing does not exceed the listed QL to avoid claim denial.

    • Examples show lidocaine products with both QL and PA (e.g., QL(30 GM per 30 days); PA).
    • Vancomycin capsules include QL values (QL(120 EA per 30 days) and QL(240 EA per 30 days)).
    Prior Authorization

    Obtain PA for PA NSO anticonvulsants

    Certain anticonvulsant products are marked 'PA NSO' in the table; prescribers must obtain prior authorization for these anticonvulsants for coverage to be approved.

    • Examples with PA NSO include BRIVIACT and EPIDIOLEX.
    • PA NSO notation indicates prior authorization is required (see introduction pages).
    Prior Authorization

    Submit PA when product row shows PA or PA NSO

    Drugs shown with 'PA' or 'PA NSO' in the Requirements/Limits column require prior authorization before coverage; review each product row for PA notation and submit PA accordingly.

    • The Requirements/Limits Key lists PA and PA NSO as authorization annotations.
    • Many specialty and higher‑tier products are annotated PA or PA NSO and will not be covered without approval.
    Prior Authorization

    PA required for specialty/oncology agents

    Many oncology, specialty, and high‑cost agents are designated 'PA' or 'PA NSO' and require prior authorization before they will be covered; providers should submit PA per plan processes for these agents.

    • Examples include PHESGO, ALECENSA, ALUNBRIG and multiple other oncology agents marked PA NSO.
    • Specialty injectable entries commonly show PA and may carry QL annotations as well.
    Prior Authorization

    PA required for multiple specific products (e.g., INBRIJA, NUPLAZID)

    Multiple listed products are marked with 'PA' or 'PA NSO' (e.g., INBRIJA, NUPLAZID, OPIPZA); prescribers must obtain prior authorization for these products to ensure coverage.

    • INBRIJA and NUPLAZID are examples shown with PA or PA NSO.
    • Check the product entry's Requirements/Limits field and follow PA submission requirements.
    Prior Authorization

    PA required for MOUNJARO, OZEMPIC and related agents

    GLP‑1 receptor agonists and related agents (e.g., MOUNJARO, OZEMPIC) are listed with PA in Requirements/Limits; prescribers must obtain prior authorization for these products.

    • MOUNJARO and OZEMPIC entries show QL values and PA annotations.
    • Submit PA per formulary instructions for GLP‑1 agents to avoid claim denial.
    Prior Authorization

    Seek PA for PA‑designated eltrombopag products

    Certain thrombopoietin receptor agonists (example: eltrombopag oral formulations) are marked 'PA' in the Requirements/Limits column; prescribers must request prior authorization for coverage.

    • Eltrombopag olamine tablet strengths are listed with Requirements/Limits = PA.
    Prior Authorization

    PA required for metyrosine 250 mg

    Metyrosine 250 mg capsules are listed with 'PA' in the Requirements/Limits column; prescribers must obtain prior authorization for this product to be covered.

    • Metyrosine capsule 250mg — Requirements/Limits = PA.
    Prior Authorization

    PA and QL required for REPATHA (3 mL/28 days)

    Both presentations of REPATHA (420 mg/3.5 mL Pushtronex and 140 mg/mL) are listed with prior authorization and a quantity limit of QL(3 mL per 28 days); prescribers must obtain PA and prescribe within this QL.

    • REPATHA PUSHTRONEX SYSTEM INJECTION 420MG/3.5ML — QL(3 ML per 28 days); PA.
    • REPATHA INJECTION 140MG/ML — QL(3 ML per 28 days); PA.
    Prior Authorization

    PA and QL required for TRYNGOLZA (3 mL/28 days)

    TRYNGOLZA injection (80 mg/0.8 mL) requires prior authorization and has a quantity limit of QL(3 mL per 28 days); submit PA and ensure prescribed volume does not exceed the QL.

    • TRYNGOLZA INJECTION 80MG/0.8ML — QL(3 ML per 28 days); PA.
    Prior Authorization

    PA and QL required for KERENDIA (30 EA/30 days)

    KERENDIA tablets (10 mg, 20 mg, 40 mg) are listed with PA and a quantity limit of QL(30 EA per 30 days); prescribers must obtain prior authorization and adhere to the 30‑unit monthly limit.

    • KERENDIA TABLET 10MG, 20MG, 40MG — QL(30 EA per 30 days); PA.
    Prior Authorization

    PA and QL required for VERQUVO (30 EA/30 days)

    VERQUVO tablets (2.5 mg, 5 mg, 10 mg) are listed with prior authorization and a quantity limit of QL(30 EA per 30 days); prescribers must obtain PA and order within the QL.

    • VERQUVO TABLET 10MG, 2.5MG, 5MG — QL(30 EA per 30 days); PA.
    Prior Authorization

    Submit PA for select specialty products (e.g., SPEVIGO, OTEZLA, LIVMARLI)

    Select products in the specialty section (for example SPEVIGO injection, OTEZLA, LIVMARLI) are shown with 'PA' and often a QL; prescribers must submit prior authorization for these items.

    • SPEVIGO INJECTION — QL(4 ML per 28 days); PA.
    • OTEZLA TABLET — QL and PA noted in specialty entries.
    • LIVMARLI TABLET/SOLUTION — QL and PA indicated.
    Prior Authorization

    PA required for select specialty/high‑cost drugs

    Specialty/high‑cost drugs throughout the formulary are designated 'PA' in Requirements/Limits; prescribers must request prior authorization before dispensing these specialty agents.

    • Examples include FABRAZYME, ONPATTRO, RIVFLOZA entries with PA and QL annotations.
    • Check each specialty product row for PA notation.
    Prior Authorization

    Obtain PA for listed specialty and select agents

    The formulary marks many specialty injectables and select oral agents with 'PA' or 'PA NSO'; prescribers must obtain prior authorization for those listed products to secure coverage.

    • Selected biologics and specialty agents show PA and product‑specific QLs.
    • PA NSO appears frequently on oncology and specialty lines.
    Prior Authorization

    PA plus QL for biologic injectables

    Many biologic injectables have both quantity limits and prior authorization (e.g., DUPIXENT, ORENCIA, ADALIMUMAB biosimilars); prescribers must obtain PA and follow the product QL when ordering.

    • DUPIXENT and ORENCIA entries include QL values and PA annotations.
    • Adalimumab biosimilars list QL per presentation and require PA.
    Prior Authorization

    PA required for multiple specialty biologics

    Numerous biologics and specialty drugs throughout the table are annotated with 'PA' or QL; prescribers must follow the PA process for these high‑tier medications before dispensing.

    • ADALIMUMAB entries show QL and PA across multiple presentations.
    • PEGASYS and other immunological agents are marked PA or PA NSO.
    Prior Authorization

    PA required for select specialty medications

    High‑tier specialty medications are marked 'PA' in the formulary; prescribers must request prior authorization for coverage of these medications.

    • Examples include RIVFLOZA entries and cystic fibrosis agents (KALYDECO, TRIKAFTA) showing QL and PA.
    • Refer to product rows for PA and QL specifics.
    Step Therapy

    Follow step therapy — try preferred agents first

    Step therapy (ST) may require trying specified preferred drugs first before the plan will cover an alternate drug; prescribers must document prior therapy failure or intolerance when requesting exceptions to a step requirement.

    • The formulary explains step therapy: the plan may not cover Drug B unless Drug A was tried first.
    • For exceptions, prescriber must provide a supporting statement explaining the medical reason.
    Step Therapy

    Adhere to ST and ST NSO rules when annotated

    Step Therapy (ST) and ST NSO (Step Therapy for New Starts Only) are defined in the Requirements/Limits key and may apply to products marked with those annotations; providers must follow the formulary's step rules where indicated.

    • ST NSO appears on specific product rows (e.g., AUVELITY, EXXUA, FETZIMA therapy packs).
    • Refer to the Requirements/Limits field for ST or ST NSO notation.
    Step Therapy

    ST NSO applies to specified products (AUVELITY, EXXUA, FETZIMA)

    Products annotated 'ST NSO' in the table indicate step therapy applies for new starts (examples include AUVELITY, EXXUA and FETZIMA); prescribers should follow the formulary's step requirements for these items.

    • AUVELITY TABLET — Requirements/Limits = QL(60 EA per 30 days); ST NSO.
    • FETZIMA therapy pack and capsules include ST NSO annotations.
    Note

    No explicit step algorithms in this segment — consult introduction

    This excerpt does not include explicit step‑therapy algorithms or step sequences; where only PA and QL flags are present, follow PA/QL rules and consult the formulary introduction for step algorithms.

    • No step sequences are documented in this extract; step rules are defined elsewhere in the formulary introduction.
    Step Therapy

    Step therapy applies to FANAPT, INVEGA and similar items

    Some products are labeled 'ST NSO' (e.g., FANAPT titration packs and INVEGA HAFYERA) indicating step therapy requirements for those items; providers must follow the plan's step therapy process for these products.

    • FANAPT titration packs — Requirements/Limits include ST NSO and QL values.
    • INVEGA HAFYERA injection entries show ST NSO.
    Note
    Documentation Required

    Include prescriber's supporting statement for exceptions

    When requesting an exception to a formulary requirement (PA, QL, ST or tiering), the prescriber must provide a supporting statement explaining the medical reasons why the exception is needed; plan decisions are generally made within 72 hours (24 hours expedited).

    • Prescriber supporting statement is required to request exceptions.
    • Standard decision timeline is 72 hours; expedited decisions within 24 hours when warranted.
    Documentation Required

    Document requirement types per Requirements/Limits key

    The formulary uses requirement type codes (PA, QL, NDS, ST and related NSO annotations); providers must follow the documentation and submission instructions referenced in the formulary introduction when seeking authorization or exception.

    • PA = Prior Authorization; QL = Quantity Limits; NDS = Non‑Extended Day Supply; ST = Step Therapy; ST NSO/PA NSO defined on introduction pages.
    Documentation Required

    Consult formulary introduction for required documentation

    Refer to the formulary introduction pages for the exact meanings and the plan's required documentation for PA NSO, QL, ST NSO and related annotations before submitting authorizations or exceptions.

    • The introduction pages define PA NSO and ST NSO and list required documentation and operational rules.
    Billing Rule

    Dispense within listed quantity limits (QL) or obtain exception

    Quantity limits (QL) are specified for many products (for example, TRINTELLIX QL(30 EA per 30 days) and Cablivi QL(30 EA per 30 days)); providers must ensure prescriptions and dispensing do not exceed the listed QL unless an approved exception/PA is granted.

    • TRINTELLIX TABLET — QL(30 EA per 30 days).
    • CABLIVI EXAMPLE — 30 tablets per 30 days.
    Documentation Required

    Follow the product Requirements/Limits field for coverage rules

    Providers must follow the Requirements/Limits key on each product row when submitting claims or requests; the product row lists the exact QL, PA, ST or other annotations that govern coverage for that drug.

    • Each entry row includes drug name, strength, Drug Tier and Requirements/Limits field which drive coverage decisions.
    • Use the product row values when preparing PA or exception submissions.
    Billing Rule

    Ensure prescriptions conform to listed QL values

    Ensure prescriptions conform to the listed quantity limits for the product; claims exceeding the QL may be denied unless prior authorization or an approved exception is obtained.

    • Examples include dabigatran QL(60 EA per 30 days) and XARELTO QL values.
    • Exceeding a QL without approval can trigger denial or reduced coverage.
    Denial Risk

    Lack of PA can lead to denial or non‑coverage

    Failure to obtain required prior authorization may result in the plan not covering the drug; prescribers should obtain PA before dispensing PA‑flagged drugs.

    • The formulary explicitly states lack of PA may result in non‑coverage.
    • Submit PA prior to fill to avoid denial at claim adjudication.
    Denial Risk

    Non‑compliance with Requirements/Limits may trigger denial

    Prescriptions that do not meet the listed Requirements/Limits (e.g., lacking PA, exceeding QL, or requesting non‑extended day supply when not allowed) may be denied; verify the product's Requirements/Limits before submitting claims.

    • Denial triggers include exceeding quantity limits, missing prior authorization, or incorrect supply types (NDS).
    • Review the Requirements/Limits field on the formulary entry to confirm requirements.
    Denial Risk

    PA/QL flags create denial risk without proper authorization

    Requests for products flagged 'PA' or for quantities above the stated QL may be denied if authorization or documentation supporting medical necessity is not provided; obtain PA or submit supporting documentation to mitigate denial risk.

    • PA/QL flags are explicit denial risk triggers in the formulary.
    • Provide requested documentation (diagnosis, prior therapy) when submitting PA.
    Prior Authorization

    PA NSO entries — obtain PA for listed anticonvulsants

    Products marked 'PA NSO' (prior authorization for new starts only) indicate prior authorization is required for coverage of those anticonvulsant or specialty items; prescribers must obtain the PA as specified to avoid denial.

    • Examples include BRIVIACT, EPIDIOLEX and FINTEPLA shown with PA NSO.
    • PA NSO notation is defined on the formulary introduction pages.
    Denial Risk

    Exceeding QL may result in denial — observe QL(...) values

    Quantity limits shown as QL(...) (for example, NAYZILAM QL(10 EA per 30 days), gabapentin QLs) represent maximum covered amounts; dispensing beyond these limits without authorization may be denied.

    • NAYZILAM SOLUTION — QL(10 EA per 30 days).
    • Gabapentin capsule and solution entries list specific QL values.
    Billing Rule

    PA, B/D or PA NSO annotations can trigger billing/authorization actions

    Drugs annotated with 'PA', 'B/D' (billing/designation) or 'PA NSO' may have special prior authorization or billing requirements that, if not met, can trigger denial or incorrect benefit application.

    • B/D indicates potential Part B vs Part D billing determination and may require plan review.
    • PA NSO and PA annotations signal prior authorization obligations.
    Prior Authorization

    PA is required for many formulary agents — obtain approval

    Numerous listed drugs are marked 'PA' across the formulary; prescribers must obtain prior authorization for PA‑listed products to reduce the risk of claim denial.

    • The Requirements/Limits table repeatedly annotates specialty agents and many biologics with PA.
    • Obtain PA in advance where required.
    Note

    PA/QL annotations imply authorization or quantity requirements

    The presence of 'PA' or 'QL' on a product row indicates the drug requires prior authorization or is subject to a quantity limit; claims lacking PA or exceeding QL may be denied or require retrospective review.

    • Check product rows for PA and QL annotations before prescribing or dispensing.
    • High‑tier and specialty drugs commonly carry PA/QL notations.
    Denial Risk

    PA/QL non‑compliance can lead to denials

    Products listed with 'PA' or with specific QL values may be denied if prior authorization is not obtained or if the quantity exceeds the stated limit; providers should secure PA and document need before dispensing.

    • SPEVIGO example: QL(4 ML per 28 days); PA — may be denied without PA.
    • Formulary notes that PA/QL non‑compliance can lead to denial.
    Prior Authorization

    Obtain PA for PA‑listed specialty products (e.g., CERDELGA, FABRAZYME)

    Claims for PA‑listed products such as CERDELGA, CHOLBAM or FABRAZYME will require prior authorization per the Requirements/Limits field; submit PA prior to dispensing to avoid claim denial.

    • FABRAZYME INJECTION — Requirements/Limits = PA.
    • CERDELGA and CHOLBAM are listed with PA in the specialty section.
    Prior Authorization

    Submit PA for products marked PA or PA NSO

    Selected agents throughout the table are annotated 'PA' or 'PA NSO'; prescribers must obtain prior authorization per the product's Requirements/Limits before dispensing.

    • Multiple entries across therapeutic classes show PA or PA NSO flags.
    • Follow the PA process for these agents to secure coverage.
    Billing Rule

    Quantity limits are enforced — exceeding QL risks denial

    Formulary QL listings indicate enforcement of maximum supplies (e.g., QL(91 EA per 91 days)); exceeding these QLs without approval may result in denial or reduced coverage.

    • Examples include contraceptive QLs (91 EA per 91 days) and other product‑specific QLs.
    • Obtain PA or exception for amounts beyond the QL.
    Denial Risk

    Claims without approved PA are subject to denial

    Claims for drugs listed with 'PA' will be subject to denial or non‑coverage if an approved prior authorization is not on file; obtain PA prior to dispensing PA‑flagged medications.

    • The formulary notes claims without approved PA will be subject to denial.
    • Submit PA documentation following plan procedures.
    Prior Authorization

    PA indicated for select high‑tier medications (e.g., RIVFLOZA)

    Several high‑tier medications (for example RIVFLOZA) are annotated 'PA' in the formulary; prescribers must obtain prior authorization to ensure coverage of these high‑cost specialty drugs.

    • RIVFLOZA INJECTION entries include QL and PA annotations.
    • High‑cost specialty entries commonly require PA.

    Step Therapy Rules

    Step therapy principle
    Try preferred drug(s) first — plan may require trial of specified preferred agents before covering alternative therapies for the same condition (step therapy).
    Step therapy presence
    Step Therapy (ST) and ST NSO (Step Therapy for New Starts Only) appear in the Requirements/Limits key and may apply to listed products as indicated in the formulary table.
    ST NSO examples
    Examples flagged ST NSO include AUVELITY (QL(60 EA per 30 days); ST NSO), EXXUA titration/therapy packs (listed with ST NSO), and FETZIMA therapy/titration packs (QL(56 EA per 365 days); ST NSO).
    Step therapy and migraine biologics
    Migraine biologics/CGRP agents (e.g., AIMOVIG, EMGALITY) are shown with quantity limits and prior authorization requirements (QL and PA). The excerpt does not list explicit step-therapy sequences for these agents.
    Step therapy sequences present?
    No explicit step-therapy algorithms or sequential step definitions are provided in this excerpt; table entries mainly annotate products with PA, QL, ST or ST NSO flags and refer readers to the formulary introduction for procedural rules.
    Examples annotated ST NSO
    Items annotated 'ST NSO' include FANAPT titration packs and FANAPT tablets (multiple titration packs listed with ST NSO) and INVEGA HAFYERA injection (Requirements/Limits = ST NSO).
    PA for some GLP-1 agents
    Certain GLP-1 and related glycemic agents (examples: MOUNJARO, OZEMPIC, TRULICITY) are shown with quantity limits and PA designations; this excerpt does not provide step therapy sequences for these agents.
    Items labeled 'ST'
    Some products are labeled 'ST' indicating step therapy applies (for example: diclofenac sodium gel is QL(300 GM per 30 days); ST; RELISTOR formulations are noted elsewhere with ST). Specific preferred-step agents and sequences are defined in the formulary introduction.
    Starter-pack / product-specific restrictions
    Starter-package and product-specific restrictions are shown for some branded starter kits — e.g., select ADALIMUMAB-ADBM starter packages are listed with QL and PA and annotated 'Boehringer Ingelheim labeled products only' as a product-specific restriction.
    Step therapy absence note
    The excerpt frequently indicates PA and QL annotations but does not enumerate explicit step-therapy step sequences or algorithms; see the formulary introduction for procedural definitions.

    Quantity Limits (QL) by Product

    Cablivi example — 30 tablets per 30 days
    CABLIVI (example)30 tablets per 30 days
    Formulary lineCABLIVI INJECTION 11MG shows QL(30 EA per 30 days)
    Provider actionPrescriptions must conform to listed QL or seek prior authorization/exception
    JOURNAVX TABLET 50MG — 30 EA per 90 days
    ProductJOURNAVX TABLET 50MG
    Quantity limit30 EA per 90 days
    Formulary annotationListed as QL(30 EA per 90 days)
    celecoxib (certain strengths) — 60 EA per 30 days
    Product/strengthscelecoxib (selected strengths)
    Quantity limit60 EA per 30 days
    Formulary contextQL(60 EA per 30 days) for listed strengths
    diclofenac sodium gel 1% — 1000 GM per 30 days
    Productdiclofenac sodium gel 1%
    Quantity limit1000 GM per 30 days
    Formulary entryQL(1000 GM per 30 days) in Requirements/Limits column
    buprenorphine patch weekly — 4 EA per 28 days
    Productbuprenorphine patch (weekly)
    Quantity limit4 EA per 28 days
    Formulary annotationQL(4 EA per 28 days) shown for patch strengths
    lidocaine/prilocaine cream 2.5%/2.5% — 30 GM
    Productlidocaine/prilocaine cream 2.5%/2.5%
    Quantity limit30 GM per 30 days
    Formulary referenceListed QL in Requirements/Limits key
    lidocaine ointment 5% — 150 GM
    Productlidocaine ointment 5%
    Quantity limit150 GM per 30 days
    NoteAlso shown for premium lidocaine ointment
    premium lidocaine ointment 5% — 150 GM
    Productpremium lidocaine ointment 5%
    Quantity limit150 GM per 30 days
    Formulary entryQL(150 GM per 30 days)
    linezolid suspension reconstituted 100mg/5ml — 1800 ML
    Productlinezolid suspension reconstituted 100mg/5ml
    Quantity limit1800 ML per 28 days
    Formulary noteQL specified for suspension presentation
    linezolid tablet 600mg — 56 EA
    Productlinezolid tablet 600mg
    Quantity limit56 EA per 28 days
    Formulary annotationQL(56 EA per 28 days)
    vancomycin capsule 125mg — 120 EA
    Productvancomycin hydrochloride capsule 125mg
    Quantity limit120 EA per 30 days
    Formulary noteQL listed for 125mg capsule
    vancomycin capsule 250mg — 240 EA
    Productvancomycin hydrochloride capsule 250mg
    Quantity limit240 EA per 30 days
    Formulary noteQL listed for 250mg capsule
    NAYZILAM SOLUTION 5MG/0.1ML — 10 EA
    ProductNAYZILAM SOLUTION 5MG/0.1ML
    Quantity limit10 EA per 30 days
    Formulary annotationQL(10 EA per 30 days)
    gabapentin capsule 400mg — 270 EA
    Productgabapentin capsule 400mg
    Quantity limit270 EA per 30 days
    Formulary contextQL listed in Requirements/Limits key
    gabapentin capsule 100mg/300mg — 360 EA
    Productgabapentin capsule 100mg / 300mg
    Quantity limit360 EA per 30 days
    Formulary noteQL for lower-strength capsule presentations
    gabapentin solution 250mg/5ml — 2160 ML
    Productgabapentin solution 250mg/5ml
    Quantity limit2160 ML per 30 days
    Formulary annotationQL specified for liquid formulation
    gabapentin tablet 800mg — 150 EA
    Productgabapentin tablet 800mg
    Quantity limit150 EA per 30 days
    Formulary noteQL shown in Requirements/Limits key
    gabapentin tablet 600mg — 180 EA
    Productgabapentin tablet 600mg
    Quantity limit180 EA per 30 days
    Formulary annotationQL specified for 600mg tablet
    pregabalin capsule 300mg — 60 EA
    Productpregabalin capsule 300mg
    Quantity limit60 EA per 30 days
    Formulary noteQL assigned in formulary table
    pregabalin capsules (25-225mg) — 90 EA
    Productpregabalin capsules (25-225mg)
    Quantity limit90 EA per 30 days
    Formulary annotationQL listed for other strengths
    VALTOCO dosing packs — 10 EA
    ProductVALTOCO dosing packs
    Quantity limit10 EA per 30 days
    Formulary entryQL(10 EA per 30 days) for dosing packs/doses
    bupropion ER 100mg — 90 EA
    Productbupropion ER 100mg
    Quantity limit90 EA per 30 days
    Formulary contextQL assigned for extended-release strengths
    bupropion ER 150/200mg — 60 EA
    Productbupropion ER 150/200mg
    Quantity limit60 EA per 30 days
    Formulary noteQL varies by ER strength
    FETZIMA TITRATION PACK — 56 EA
    ProductFETZIMA TITRATION PACK
    Quantity limit56 EA (therapy pack) per 365 days
    Formulary annotationQL(56 EA per 365 days); ST NSO for titration pack
    DRIZALMA SPRINKLE CAPSULE 20/60MG — 60 EA
    ProductDRIZALMA SPRINKLE CAPSULE (20/60mg)
    Quantity limit60 EA per 30 days
    Formulary noteQL listed for 20/60mg strengths
    DRIZALMA SPRINKLE CAPSULE 30/40MG — 90 EA
    ProductDRIZALMA SPRINKLE CAPSULE (30/40mg)
    Quantity limit90 EA per 30 days
    Formulary annotationQL listed for 30/40mg strengths
    desvenlafaxine ER 100mg — 120 EA
    Productdesvenlafaxine ER 100mg
    Quantity limit120 EA per 30 days
    Formulary contextQL specified for 100mg strength
    TRINTELLIX TABLET 5/10/20 mg — QL(30 EA per 30 days)
    ProductTRINTELLIX tablets (5/10/20 mg)
    Quantity limitQL(30 EA per 30 days)
    Formulary annotationQL listed in Requirements/Limits key
    aprepitant capsule therapy pack entries — various QL values
    Productaprepitant capsule therapy pack / 40/80/125mg
    Quantity limitsQL examples: 6 EA per 30 days; 1 EA per 30 days; 8 EA per 30 days; 2 EA per 30 days
    Formulary noteSome aprepitant entries also carry B/D annotation
    AIMOVIG INJECTION 70/140 mg — QL(1 ML per 28 days); QL(2 ML per 28 days)
    ProductAIMOVIG INJECTION 70/140 mg
    Quantity limitsQL(1 ML per 28 days) and QL(2 ML per 28 days) depending on presentation
    Formulary annotationQL and PA specified for CGRP agents
    sumatriptan succinate tablet — QL(9 EA per 30 days)
    Productsumatriptan succinate tablet
    Quantity limitQL(9 EA per 30 days)
    Formulary contextQL shown in migraine agent listings
    terbinafine 250mg — QL(84 EA per 180 days)
    Productterbinafine 250mg
    Quantity limitQL(84 EA per 180 days)
    Formulary noteQL period specified as 180 days for this antifungal
    Multiple QL examples — 30/60/90/120/180 EA per 30 days, 28 day packs etc.
    Common QL examples30/60/90/120/180 EA per 30 days; 28-day pack QLs; 365-day packet QLs
    ApplicabilityObserved across oncology, HIV, CNS and other drug sections
    GuidanceFollow product-specific QL in the formulary Requirements/Limits column
    aripiprazole ODT — 60 EA
    Productaripiprazole ODT
    Quantity limit60 EA per 30 days
    Formulary annotationQL(60 EA per 30 days)
    aripiprazole solution 1mg/ml — 750 ML
    Productaripiprazole solution 1mg/ml
    Quantity limit750 ML per 30 days
    Formulary noteLiquid presentation QL shown in table
    CAPLYTA — 30 EA
    ProductCAPLYTA
    Quantity limit30 EA per 30 days
    Formulary annotationQL shown in Requirements/Limits key
    lurasidone HCl — 30 EA
    Productlurasidone HCl (various strengths)
    Quantity limit30 EA per 30 days
    Formulary entryQL specified for listed strengths
    clozapine tablets — examples 120/180/270 EA per 30 days
    Productclozapine tablets (various strengths)
    Quantity limitsExamples: 120 EA, 180 EA, 270 EA per 30 days depending on strength
    Formulary noteQL varies by strength as listed
    VERSACLOZ suspension — 540 ML
    ProductVERSACLOZ suspension
    Quantity limit540 ML per 30 days
    Formulary annotationQL(540 ML per 30 days)
    MAVYRET — 560 EA or 336 EA per 365 days
    ProductMAVYRET (packet/tablet)
    Quantity limits560 EA per 365 days (packet) or 336 EA per 365 days (tablet)
    Formulary noteYearly packet/tablet QLs shown in HCV section
    Selected HIV agents — QL examples
    Selected HIV agentsExamples include QL(30 EA per 30 days), QL(60 EA per 30 days), QL(180 EA per 30 days)
    ApplicabilityQLs depend on agent and formulation (packets/tablets)
    ReferenceSee Anti-HIV sections for product-specific QLs
    rilpivirine 25mg — 30
    Productrilpivirine 25mg tablet
    Quantity limit30 EA per 30 days
    Formulary annotationQL(30 EA per 30 days)
    abacavir 300mg — 60
    Productabacavir 300mg tablet
    Quantity limit60 EA per 30 days
    Formulary noteQL(60 EA per 30 days)
    emtricitabine/tenofovir — 30
    Productemtricitabine/tenofovir tablets
    Quantity limit30 EA per 30 days
    Formulary contextCommon per-30-day QL for many HIV fixed-dose products
    TRIUMEQ PD TABLET SOLUBLE — 180
    ProductTRIUMEQ PD tablet soluble
    Quantity limit180 EA per 30 days
    Formulary notePacket/soluble presentation QL shown in table
    darunavir 800mg — 30
    Productdarunavir 800mg tablet
    Quantity limit30 EA per 30 days
    Formulary annotationQL(30 EA per 30 days)
    oseltamivir 75mg — 110
    Productoseltamivir 75mg capsule
    Quantity limit110 EA per 365 days
    Formulary noteYear-based QL for antiviral prophylaxis/treatment
    MOUNJARO injection — 2
    ProductMOUNJARO injection (various strengths)
    Quantity limit2 (ML) per 28 days
    Formulary annotationQL(2 ML per 28 days); PA often applies
    OZEMPIC injection — 3
    ProductOZEMPIC injection (various strengths)
    Quantity limit3 (ML) per 28 days
    Formulary noteQL(3 ML per 28 days); PA indicated
    PAXLOVID therapy pack — 11-30
    ProductPAXLOVID therapy pack (various)
    Quantity limitsRange observed: 11-30 (per pack/therapy course)
    Formulary annotationQL expressed per 5-day therapy pack sizes
    dabigatran — QL(60 EA per 30 days)
    Productdabigatran etexilate capsules
    Quantity limitQL(60 EA per 30 days)
    Formulary noteAnticoagulant QL shown in Requirements/Limits key
    ELIQUIS STARTER PACK — QL(148 EA per 365 days)
    ProductELIQUIS starter pack (5mg) therapy pack
    Quantity limitQL(148 EA per 365 days)
    Formulary contextStarter/therapy pack yearly QL shown
    CABLIVI INJECTION 11MG — QL(30 EA per 30 days)
    ProductCABLIVI Injection 11mg
    Quantity limitQL(30 EA per 30 days)
    Formulary noteExample QL for Cablivi shown in table
    ENTRESTO capsule sprinkle — QL(240 EA per 30 days)
    ProductENTRESTO capsule sprinkle
    Quantity limitQL(240 EA per 30 days)
    Formulary annotationPacket/sprinkle presentation QL shown
    XARELTO suspension — QL(600 ML per 30 days)
    ProductXARELTO suspension reconstituted 1mg/ml
    Quantity limitQL(600 ML per 30 days)
    Formulary noteLiquid suspension QL listed in Requirements/Limits key
    XARELTO tablet — QL(30 EA per 30 days)
    ProductXARELTO tablet 10mg/20mg
    Quantity limitQL(30 EA per 30 days)
    Formulary contextCommon per-30-day tablet QL
    ENTRESTO strength-specific QL
    ProductENTRESTO capsule sprinkle (strength-specific)
    Quantity limitQL(240 EA per 30 days)
    Formulary noteStrength-specific QL entries present in table
    ivabradine — QL(60 EA per 30 days)
    Productivabradine hydrochloride tablet
    Quantity limitQL(60 EA per 30 days)
    Formulary annotationQL listed in cardiovascular section
    sacubitril/valsartan — QL(60 EA per 30 days)
    Productsacubitril/valsartan (ENTRESTO)
    Quantity limitQL(60 EA per 30 days)
    Formulary noteQL shown in cardiac agents section
    VYNDAMAX capsule 61mg — QL(30 EA per 30 days)
    ProductVYNDAMAX capsule 61mg
    Quantity limitQL(30 EA per 30 days)
    Formulary annotationQL provided in Requirements/Limits key
    REPATHA — QL(3 ML per 28 days)
    ProductREPATHA (both forms)
    Quantity limitQL(3 ML per 28 days)
    RequirementPA plus QL for PCSK9 agents
    TRYNGOLZA — QL(3 ML per 28 days)
    ProductTRYNGOLZA injection 80mg/0.8mL
    Quantity limitQL(3 ML per 28 days)
    Formulary noteQL and PA indicated for this agent
    KERENDIA tablet — QL(30 EA per 30 days)
    ProductKERENDIA tablet (10/20/40mg)
    Quantity limitQL(30 EA per 30 days)
    RequirementPA also listed for KERENDIA
    FARXIGA tablet — QL(30 EA per 30 days)
    ProductFARXIGA tablet
    Quantity limitQL(30 EA per 30 days)
    Formulary contextCommon SGLT2 per-30-day QL
    JARDIANCE tablet — QL(30 EA per 30 days)
    ProductJARDIANCE tablet
    Quantity limitQL(30 EA per 30 days)
    Formulary noteQL shown for empagliflozin formulations
    ADHD stimulant QLs — 60 or 90 EA per 30 days
    ADHD stimulant QLsQL(60 or 90 EA per 30 days) depending on product
    ApplicabilityExtended-release and immediate-release products have different QLs
    Formulary instructionRefer to product row for exact QL
    COBENFY starter/regular; BETASERON; dalfampridine examples
    COBENFY packsStarter: QL(112 EA per 365 days); Regular: QL(60 EA per 30 days)
    BETASERONQL(15 EA per 30 days)
    dalfampridine ERQL(60 EA per 30 days)
    BETASERON — QL(15 EA per 30 days)
    BETASERON injectionQL(15 EA per 30 days)
    RequirementPA may apply for some MS agents
    Formulary noteSee MS agents block for QL/PA details
    Selected topical formulation QLs — varied GM/ML limits
    Topical formulation examplesQL values range (e.g., 50–120 GM per 30 days; 60 ML per 30 days)
    Products citedtazarotene, fluocinonide, hydrocortisone, calcipotriene etc.
    Formulary guidanceGram (GM) or milliliter (ML) units used for topical QLs
    EUCRISA; fluocinonide; diclofenac gel — topical QLs
    EUCRISA OINTMENT 2%QL(120 GM per 30 days)
    fluocinonide cream 0.05%QL(60 GM per 30 days)
    diclofenac sodium gel 3%QL(300 GM per 30 days)
    JYNARQUE TABLET — QL(120 EA per 30 days)
    ProductJYNARQUE tablet 15/30mg
    Quantity limitQL(120 EA per 30 days)
    Formulary notePA may apply; QL specified
    LIVMARLI SOLUTION — QL(60 ML per 30 days)
    ProductLIVMARLI solution 19mg/mL
    Quantity limitQL(60 ML per 30 days)
    RequirementPA noted in formulary for some LIVMARLI entries
    Selected biologics and specialty injectable QLs
    Biologics/selected injectablesProduct-specific QLs (e.g., QL(4 ML per 28 days); QL(3 ML per 28 days); QL(20 ML per 28 days))
    PA statusMany biologics also carry PA/PA NSO annotations
    Unit/periodQLs commonly expressed in mL per 28/30/84/365 days

    Site of Care and Dispensing

    Note

    Verify site‑of‑care — retail, mail order, and LTC have different rules

    Mail order, long‑term care (LTC) and retail settings have different coverage, copay and supply rules; verify the site‑of‑care (retail vs mail vs LTC) because coverage and supply limits (e.g., LTC 31‑day supply) and cost‑sharing vary by setting.

    • Long‑term care entries note a 31‑day supply and differing copays/coinsurance.
    • Mail order and retail copays differ by tier and setting.

    Definitions and Key Terms

    Background

    The formulary is organized by medical condition and drug class to support both an index and alphabetical lookup. The document also explains biosimilars and notes that some biosimilars may be designated interchangeable, allowing substitution for the reference biological product in accordance with state law; the plan may add biosimilars and adjust tiering or restrictions for the original biological product when a biosimilar is added.

    Note

    Biosimilar substitutions and tier changes possible — monitor formulary updates

    The plan may add biosimilar versions and change tiering or restrictions for original biologics; providers should expect possible immediate substitution or tier changes per the formulary and follow state substitution rules for interchangeable biosimilars.

    • When adding an interchangeable biosimilar, the plan may move the original biologic to a different tier or add restrictions.
    • Substitution of interchangeable biosimilars may occur according to state law.